Payment overview · 2025
General Payments
$480.25
34 reported records · 9 companies
Healthcare provider profile · identity verified
Joseph N Gabriel, MD
Allopathic & Osteopathic Physicians|Internal Medicine · IRMO, SC · NPI 1093773590
Verified facts
What the public records show
CMS Open Payments records show Joseph N Gabriel, MD received $480.25 in general payments during 2025 across 34 reported records.
ABBVIE INC. accounted for 29.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Linzess, Ozempic, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $143.10 | 29.8% | 14 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $120.15 | 25.0% | 8 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$58.78 | 12.2% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $34.36 | 7.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.00 | 6.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $30.28 | 6.3% | 2 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $21.93 | 4.6% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $21.60 | 4.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.05 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $480.25 | 34 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $121.85 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $121.85 | 10 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $58.78 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $34.36 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.00 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $30.28 | 2 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $21.93 | 1 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $21.60 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $18.05 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $14.34 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $14.34 | 3 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $6.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 71 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
59 | 17 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
71 | 19 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 491 | 141 |
| Amlodipine Besylate | Amlodipine Besylate | 375 | 111 |
| Atorvastatin Calcium | Atorvastatin Calcium | 352 | 112 |
| Alprazolam | Alprazolam | 277 | 55 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 267 | 88 |
| Omeprazole | Omeprazole | 265 | 88 |
| Zolpidem Tartrate | Zolpidem Tartrate | 264 | 58 |
| Lisinopril | Lisinopril | 198 | 55 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 195 | 27 |
| Losartan Potassium | Losartan Potassium | 190 | 63 |
| Pantoprazole Sodium | Pantoprazole Sodium | 180 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 177 | 60 |
| Clonazepam | Clonazepam | 173 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 159 | 34 |
| Lorazepam | Lorazepam | 156 | 30 |
| Gabapentin | Gabapentin | 151 | 46 |
| Tramadol Hcl | Tramadol Hcl | 139 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 132 | 46 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 131 | 40 |
| Trazodone Hcl | Trazodone Hcl | 131 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 127 | 41 |
| Montelukast Sodium | Montelukast Sodium | 127 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 126 | 43 |
| Simvastatin | Simvastatin | 126 | 34 |
| Prednisone | Prednisone | 121 | 71 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 119 | 35 |
| Meloxicam | Meloxicam | 119 | 35 |
| Furosemide | Furosemide | 116 | 46 |
| Duloxetine Hcl | Duloxetine Hcl | 110 | 29 |
| Metformin Hcl | Metformin Hcl | 105 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 97 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 97 | 41 |
| Eliquis | Apixaban | 94 | 24 |
| Allopurinol | Allopurinol | 85 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 84 | 28 |
| Famotidine | Famotidine | 83 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 83 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 82 | 26 |
| Pregabalin | Pregabalin | 82 | 17 |
| Potassium Chloride | Potassium Chloride | 79 | 25 |
| Glimepiride | Glimepiride | 76 | 22 |
| Xarelto | Rivaroxaban | 75 | 22 |
| Ozempic | Semaglutide | 71 | 19 |
| Carvedilol | Carvedilol | 70 | 22 |
| Jardiance | Empagliflozin | 65 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 61 | 14 |
| Sertraline Hcl | Sertraline Hcl | 59 | 21 |
| Synthroid | Levothyroxine Sodium | 59 | 17 |
| Atenolol | Atenolol | 57 | 19 |
| Finasteride | Finasteride | 57 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | 16 |
| Morphine Sulfate Er | Morphine Sulfate | 57 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 57 | 38 |
| Diclofenac Sodium | Diclofenac Sodium | 56 | 19 |
| Metformin Hcl Er | Metformin Hcl | 56 | 21 |
| Donepezil Hcl | Donepezil Hcl | 54 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 52 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 49 | 14 |
| Ezetimibe | Ezetimibe | 49 | 18 |
| Celecoxib | Celecoxib | 47 | 17 |
| Promethazine Hcl | Promethazine Hcl | 47 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 43 | 16 |
| Temazepam | Temazepam | 43 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 38 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 37 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 37 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | 14 |
| Bupropion Xl | Bupropion Hcl | 35 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 35 | 11 |
| Valsartan | Valsartan | 35 | 12 |
| Ibuprofen | Ibuprofen | 34 | 14 |
| Linzess | Linaclotide | 33 | suppressed |
| Mirtazapine | Mirtazapine | 33 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 33 | 22 |
| Cefdinir | Cefdinir | 32 | 31 |
| Ipratropium Bromide | Ipratropium Bromide | 32 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | 12 |
| Glipizide Er | Glipizide | 31 | suppressed |
| Irbesartan | Irbesartan | 31 | 11 |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | 13 |
| Alendronate Sodium | Alendronate Sodium | 30 | 12 |
| Diazepam | Diazepam | 30 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Fluconazole | Fluconazole | 29 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 22 |
| Oxycodone Hcl | Oxycodone Hcl | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | 16 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 26 | suppressed |
| Ramipril | Ramipril | 26 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 13 |
| Baclofen | Baclofen | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 12 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 24 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | suppressed |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Fentanyl | Fentanyl | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Carisoprodol | Carisoprodol | 22 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Klor-Con M20 | Potassium Chloride | 19 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 14 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 11 |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 13 | suppressed |
| Diovan Hct | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $480.25 · 34 records | ABBVIE INC. | BOTOX, CLOTTRIEVER BOLD CATHETER, CREON, FARXIGA, INTELLIS ADAPTIVESTIM, LINZESS, Ozempic, QULIPTA, REXULTI, UBRELVY, Veozah, WaveWriter Alpha Prime 16 | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error